Most Read Articles
Saras Ramiya, 2 days ago
Mundipharma has launched Betadine® Natural Defense personal care product range in Malaysia in collaboration with Watsons.
18 Apr 2018
In patients with rheumatoid arthritis (RA), temporary cessation of methotrexate (MTX) treatment for 2 weeks following influenza vaccination appears to improve the immunogenicity of the vaccine without increasing RA disease activity, according to a study.
Saras Ramiya, Yesterday
The Malaysian Pharmacy Students’ Association (MyPSA) has successfully organized the 13th National Gathering of Pharmacy Students (NoGAPS) in September.
Jairia Dela Cruz, 03 May 2018
Acute coronary syndrome (ACS) patients with diabetes mellitus, as well as high-risk nondiabetic patients, appear to obtain significant cardioprotection from the addition of ezetimibe to simvastatin, and this benefit is achieved without compromising safety, according to an exploratory analysis of data from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).

Emerging role of lipoprotein(a) lowering for CVD risk reduction

10 Oct 2018

Pathophysiological, epidemiological and genetic studies provide strong evidence that lipoprotein(a) [Lp(a)] is a causal, independent risk factor for cardiovascular disease (CVD) and calcific aortic valve disease (CAVD). [J Am Coll Cardiol 2017;69:692-711]

According to Professor Sotirios Tsimikas from the University of California San Diego, US, the estimated global population with elevated Lp(a) >50 mg/dL is 1.43 billion, and the associated risk is consistent across a broad spectrum of patients, including those with LDL-cholesterol <70 mg/dL. Hence, clinical guidelines now recommend considering Lp(a) screening and treatment for high-risk individuals, such as those with familial hypercholesterolaemia, or those with recurrent CVD despite optimal lipid lowering. [J Am Coll Cardiol 2018;71:177-192; Eur Heart J 2016;37:2999-3058]

Current therapies such as mipomersen and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors lower Lp(a) by 20–30 percent, but are not indicated for Lp(a) lowering as such.  Emerging RNA-targeted therapeutics are the first to be specifically evaluated in randomized trials of Lp(a) lowering in individuals with high baseline Lp(a).

“Results are promising. For instance, the antisense oligonucleotide [ASO] IONIS-APO(a) produced dose-dependent reductions in Lp(a) levels of around 80 percent, with no apparent safety concerns,” reported Tsimikas. [Lancet 2016;388:2239-2253] Another ASO, AKCEA-APO(a), is now under phase I trial. [https://clinicaltrials.gov/ct2/show/NCT03070782]

“Specific therapies currently in clinical development will allow us to test the Lp(a) hypothesis that lowering elevated Lp(a) levels will lead to improved clinical outcomes,” he concluded.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Saras Ramiya, 2 days ago
Mundipharma has launched Betadine® Natural Defense personal care product range in Malaysia in collaboration with Watsons.
18 Apr 2018
In patients with rheumatoid arthritis (RA), temporary cessation of methotrexate (MTX) treatment for 2 weeks following influenza vaccination appears to improve the immunogenicity of the vaccine without increasing RA disease activity, according to a study.
Saras Ramiya, Yesterday
The Malaysian Pharmacy Students’ Association (MyPSA) has successfully organized the 13th National Gathering of Pharmacy Students (NoGAPS) in September.
Jairia Dela Cruz, 03 May 2018
Acute coronary syndrome (ACS) patients with diabetes mellitus, as well as high-risk nondiabetic patients, appear to obtain significant cardioprotection from the addition of ezetimibe to simvastatin, and this benefit is achieved without compromising safety, according to an exploratory analysis of data from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).